Interventional left atrial appendage closure vs novel anticoagulation agents in patients with atrial fibrillation indicated for long-term anticoagulation (PRAGUE-17 study) - 18/04/17
, Petr Tousek, MD, PhD a, Dalibor Herman, MD, PhD a, Petr Neuzil, MD, CSc b, Pavel Hala, MD b, Josef Stasek, MD, PhD c, Ludek Haman, MD, PhD c, Petr Kala, MD, PhD d, Martin Poloczek, MD d, Marian Branny, MD, PhD e, Jan Chovancik, MD e, Pavel Cervinka, MD, PhD f, Jiri Holy, MD f, Vlastimil Vancura, MD, PhD g, Richard Rokyta, MD, PhD g, Milos Taborsky, MD, CSc h, Tomas Kovarnik, MD, PhD i, David Zemanek, MD, PhD i, Petr Peichl, MD, PhD j, Sarka Haskova, Eng k, Jiri Jarkovsky, Eng k, Petr Widimsky, MD, DrSc aon behalf of the
PRAGUE-17 Investigators
Background |
Atrial fibrillation (AF), with a prevalence of 1% to 2%, is the most common cardiac arrhythmia. Without antithrombotic treatment, the annual risk of a cardioembolic event is 5% to 6%. The source of a cardioembolic event is a thrombus, which is usually formed in the left atrial appendage (LAA). Prevention of cardioembolic events involves treatment with anticoagulant drugs: either vitamin K antagonists or, recently, novel oral anticoagulants (NOAC). The other (nonpharmacologic) option for the prevention of a cardioembolic event involves interventional occlusion of the LAA.
Objective |
To determine whether percutaneous LAA occlusion is noninferior to treatment with NOAC in AF patients indicated for long-term systemic anticoagulation.
Study design |
The trial will be a prospective, multicenter, randomized noninferiority trial comparing 2 treatment strategies in moderate to high-risk AF patients (ie, patients with history of significant bleeding, or history of cardiovascular event(s), or a with CHA2DS2VASc ≥3 and HAS-BLED score ≥2). Patients will be randomized into a percutaneous LAA occlusion (group A) or a NOAC treatment (group B) in a 1:1 ratio; the randomization was done using Web-based randomization software. A total of 396 study participants (198 patients in each group) will be enrolled in the study. The primary end point will be the occurrence of any of the following events within 24months after randomization: stroke or transient ischemic attack (any type), systemic cardioembolic event, clinically significant bleeding, cardiovascular death, or a significant periprocedural or device-related complications.
Conclusion |
The PRAGUE-17 trial will determine if LAA occlusion is noninferior to treatment with NOAC in moderate- to high-risk AF patients.
Le texte complet de cet article est disponible en PDF.Plan
| RCT No: NCT02426944. |
|
| Financial support: Research grant from the Ministry of Health Czech Republic (AZV 15-29565A). |
|
| Conflicts of interests: None. |
Vol 183
P. 108-114 - janvier 2017 Retour au numéro
Article précédent
- Acute cardioversion vs a wait-and-see approach for recent-onset symptomatic atrial fibrillation in the emergency department: Rationale and design of the randomized ACWAS trial
- Elton Dudink, Brigitte Essers, Wouter Holvoet, Bob Weijs, Justin Luermans, Hemanth Ramanna, Anho Liem, Jurren van Opstal, Lukas Dekker, Vincent van Dijk, Timo Lenderink, Otto Kamp, Lennert Kulker, Michiel Rienstra, Bas Kietselaer, Marco Alings, Jos Widdershoven, Joan Meeder, Martin Prins, Isabelle van Gelder, Harry Crijns
- Prevalence and outcome of thrombotic and embolic complications in adults after Fontan operation
- Alexander C. Egbe, Heidi M. Connolly, Talha Niaz, Vidhushei Yogeswaran, Nathaniel W. Taggart, Muhammad Y. Qureshi, Joseph T. Poterucha, Arooj Razzaq Khan, David J. Driscoll
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?